Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC118 in Claudin 18.2 Positive Advanced Solid Tumors
NCT05205850Phase 2Recruiting
- Sponsor
- RemeGen
- Start
- Mar 2022
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RC118 in gastric cancer (GC), esophageal cancer, gastroesophageal junction cancer and 4 more, sponsored by RemeGen. Primary endpoints: Dose Limiting Toxicity at 28 days, Adverse Events Incidence and 1 more. Started Mar 2022; status: recruiting.
02
Drugs
RC118
03
Conditions
gastric cancer (GC)esophageal cancergastroesophageal junction cancerpancreatic cancer (PC)ovarian cancer
Beyond the preview
Go deeper on NCT05205850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05205850.